Analysts are Increasing Price Targets of These 5 Stocks

2. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 75

Berenberg improved its price target for Eli Lilly and Company (NYSE:LLY) from $345 per share to $375 per share on Tuesday, November 22. The research firm acknowledged the solid underlying performance of the company despite currency challenges.

Separately, Eli Lilly and Company (NYSE:LLY) also appeared in the third-quarter 2022 investor letter of investment management firm ClearBridge Investments. Here’s what the firm said:

“In the U.S., we initiated a position in pharmaceutical maker Eli Lilly (NYSE:LLY) as it brings out new drug candidates for diabetes and Alzheimer’s disease. New drugs impact diabetes but have also demonstrated significant weight loss for patients who are overweight and have other co-morbidity issues as a result. Lilly is one of the two key players in diabetes care and we believe the potential market opportunity is much higher than the consensus forecasts as we are seeing evidence of accelerating adoption.”

Follow Eli Lilly & Co (NYSE:LLY)